medigraphic.com
Instituto Nacional de Salud Pública

2020, Número 5

<< Anterior Siguiente >>

salud publica mex 2020; 62 (5)


Patrones de edad de infección por el virus del papiloma humano como prueba primaria en el tamizaje de cáncer de cuello uterino y triaje posterior con inspección visual en Honduras

Sandoval M, Holme F, Lobo S, Slavkovsky R, Thomson KA, Jeronimo J, Figueroa J, de Sanjose S

Idioma: Ingles.
Referencias bibliográficas: 21
Paginas: 487-493
Archivo PDF: 315.30 Kb.


RESUMEN

Objetivo. Evaluar la prevalencia del virus del papiloma humano (VPH) y la positividad a la inspección visual con ácido acético (IVA) de cáncer cervicouterico, según edad en mujeres tamizadas en Honduras. Material y métodos. Se extrajo información sobre la prueba de VPH (careHPV) y de IVA en tres provincias en el ámbito de la Atención Pública en Salud. Resultados. Durante 2015-2018, 60 883 mujeres de 15-85 años fueron tamizadas, 15% fueron VPH positivas con valores máximos en mujeres de 20-24 años (27.8%), con una disminución a 16% entre 30-49 años. Se observaron diferencias mínimas entre provincias, con un patrón de edad similar. La IVA fue positiva en 24.5% en mujeres de 30-44 años, con una posterior disminución. Conclusiones. La curva de prevalencia del VPH respalda el tamizar con VPH a los 30+ años. La baja positividad de la IVA en edades cercanas a la menopausia sugiere una subdetección de lesiones cervicales en este grupo.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJF, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524-32. https://doi.org/10.1016/S0140-6736(13)62218-7

  2. Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: metaanalysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789-99. https://doi.org/10.1086/657321

  3. Franceschi S, Herrero R, Clifford GM, Snijders PJF, Arslan A, Anh PTH, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer. 2006;119(11):2677-84. https://doi. org/10.1002/ijc.22241

  4. Schiffman M, Doorbar J, Wentzensen N, de Sanjosé S, Fakhry C, Monk BJ, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primer. 2016;2:16086. https://doi.org/10.1038/nrdp.2016.86

  5. World Health Organization. WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention [Internet]. Geneva: WHO, 2013 [cited Aug 13, 2019]. Available from: http://www.ncbi. nlm.nih.gov/books/NBK195239/

  6. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492

  7. Hall MT, Smith MA, Lew J-B, O’Hallahan J, Fentiman G, Neal H, et al. The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications. Gynecol Oncol. 2019;152(3):472-9. https://doi.org/10.1016/j.ygyno.2018.10.045

  8. de Sanjose S, Brotons M, LaMontagne DS, Bruni L. Human papillomavirus vaccine disease impact beyond expectations. Curr Opin Virol. 2019;39:16-22. https://doi.org/10.1016/j.coviro.2019.06.006

  9. Brotherton JML. The remarkable impact of bivalent HPV vaccine in Scotland. BMJ. 2019;365: l1375. https://doi.org/10.1136/bmj.l1375

  10. Maza M, Alfaro K, Garai J, Velado MM, Gage JC, Castle PE, et al. Cervical cancer prevention in El Salvador (CAPE)-An HPV testing-based demonstration project: Changing the secondary prevention paradigm in a lower middle-income country. Gynecol Oncol Rep. 2017;20:58-61. https://doi. org/10.1016/j.gore.2017.02.011

  11. Toliman PJ, Kaldor JM, Badman SG, Gabuzzi J, Silim S, Kumbia A, et al. Performance of clinical screening algorithms comprising point-of-care HPV-DNA testing using self-collected vaginal specimens, and visual inspection of the cervix with acetic acid, for the detection of underlying high-grade squamous intraepithelial lesions in Papua New Guinea. Papillomavirus Res. 2018;6:70-6. https://doi.org/10.1016/j.pvr.2018.10.009

  12. Hu L, Bell D, Antani S, Xue Z, Yu K, Horning MP, et al. An observational study of deep learning and automated evaluation of cervical images for cancer screening. J Natl Cancer Inst. 2019;111(9):923-32. https://doi. org/10.1093/jnci/djy225

  13. Holme F, Jeronimo J, Maldonado F, Camel C, Sandoval M, Martinez- Granera B, et al. Introduction of HPV testing for cervical cancer screening in Central America: the Scale-Up project. Prev Med. 2020;135:106076. https://doi.org/10.1016/j.ypmed.2020.106076

  14. Herrero R, González P, Markowitz LE. Present status of human papillomavirus vaccine development and implementation. Lancet Oncol. 2015;16(5):e206-16. https://doi.org/10.1016/S1470-2045(14)70481-4

  15. Pinto D da S, Fuzii HT, Quaresma JAS. Prevalência de infecção genital pelo HPV em populações urbana e rural da Amazônia Oriental Brasileira. Cad Saúde Pública. 2011;27(4):769-78. https://doi.org/10.1590/S0102- 311X2011000400016

  16. de Lima Soares V, de Mesquita AMTS, Cavalcante FGT, Silva ZP, Hora V, Diedrich T, et al. Sexually transmitted infections in a female population in rural north-east Brazil: prevalence, morbidity and risk factors. Trop Med Int Health TM IH. 2003;8(7):595-603. https://doi.org/10.1046/j.1365- 3156.2003.01078.x

  17. Kasamatsu E, Rodríguez-Riveros MI, Soilan AM, Ortega M, Mongelós P, Páez M, et al. Factors associated with high-risk human papillomavirus infection and high-grade cervical neoplasia: A population-based study in Paraguay. PloS One. 2019;14(6):e0218016. https://doi.org/10.1371/journal. pone.0218016

  18. Raifu AO, El-Zein M, Sangwa-Lugoma G, Ramanakumar A, Walter SD, Franco EL, et al. Determinants of Cervical Cancer Screening Accuracy for Visual Inspection with Acetic Acid (VIA) and Lugol’s Iodine (VILI) Performed by Nurse and Physician. PloS One. 2017;12(1):e0170631. https:// doi.org/10.1371/journal.pone.0170631

  19. Castle P, Qiao Y-L, Zhao FH, Chen W, Valdez M, Zhang X, et al. Clinical determinants of a positive visual inspection after treatment with acetic acid for cervical cancer screening. BJOG. 2014;121(6):739-46. https://doi. org/10.1111/1471-0528.12646

  20. Mustafa RA, Santesso N, Khatib R, Mustafa AA, Wiercioch W, Kehar R, et al. Systematic reviews and meta-analyses of the accuracy of HPV tests, visual inspection with acetic acid, cytology, and colposcopy. Int J Gynecol Obstet. 2016;132(3):259-65. https://doi.org/10.1016/j.ijgo.2015.07.024

  21. Sandoval M, Slavkovsky R, Bansil P, Lim J, Figueroa J, de Sanjose S. Acceptability and safety of thermal ablation for the treatment of precancerous cervical lesions in Honduras. Trop Med Int Health. 2019;24(12):1391-99. https://doi.org/10.1111/tmi.13315




2020     |     www.medigraphic.com